PMID- 31909470
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210511
IS  - 1898-018X (Electronic)
IS  - 1897-5593 (Print)
IS  - 1898-018X (Linking)
VI  - 26
IP  - 6
DP  - 2019
TI  - Comparative effectiveness of torasemide versus furosemide in symptomatic therapy 
      in heart failure patients: Preliminary results from the randomized TORNADO trial.
PG  - 661-668
LID - 10.5603/CJ.a2019.0114 [doi]
AB  - BACKGROUND: Recent reports suggest that torasemide might be more beneficial than 
      furosemide in patients with symptomatic heart failure (HF). The aim was to 
      compare the effects of torasemide and furosemide on clinical outcomes in HF 
      patients. METHODS: This study pilot consisted of data from the ongoing 
      multicenter, randomized, unblinded endpoint phase IV TORNADO (NCT01942109) study. 
      HF patients in New York Heart Association (NYHA) II-IV class with a stable dose 
      of furosemide were randomized to treatment with equipotential dose of torasemide 
      (4:1) or continuation of unchanged dose of furosemide. On enrollment and control 
      visit (3 months after enrollment) clinical examination, 6-minute walk test (6MWT) 
      and assessment of fluid retention by ZOE Fluid Status Monitor were performed. The 
      primary endpoint was a composite of improvement of NYHA class, improvement of at 
      least 50 m during 6MWT and decrease in fluid retention of at least 0.5 W after 
      3-months follow-up. RESULTS: The study group included 40 patients (median age 66 
      years; 77.5% male). During follow-up 7 patients were hospitalized for HF 
      worsening (3 in torasemide and 4 in furosemide-treated patients). The primary 
      endpoint reached 15 (94%) and 14 (58%) patients on torasemide and furosemide, 
      respectively (p = 0.03). CONCLUSIONS: In HF patients treated with torasemide 
      fluid overload and symptoms improved more than in the furosemide group. This 
      positive effect occurred already within 3-month observation.
FAU - Balsam, Pawel
AU  - Balsam P
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Ozieranski, Krzysztof
AU  - Ozieranski K
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Marchel, Michal
AU  - Marchel M
AD  - I Katedra i Klinika Kardiologii, Poland. michal.marchel@wum.edu.pl.
FAU - Gawalko, Monika
AU  - Gawalko M
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Niedziela, Lukasz
AU  - Niedziela L
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Tyminska, Agata
AU  - Tyminska A
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Sieradzki, Bartosz
AU  - Sieradzki B
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Sieradzki, Maciej
AU  - Sieradzki M
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Fojt, Anna
AU  - Fojt A
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Bakula, Elwira
AU  - Bakula E
AD  - Cardiology Unit, John Paul II Western Hospital, ul. Daleka 11, 05-825 Grodzisk 
      Mazowiecki, Poland.
FAU - Glowczynska, Renata
AU  - Glowczynska R
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Peller, Michal
AU  - Peller M
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Markulis, Maciej
AU  - Markulis M
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Bednarski, Janusz
AU  - Bednarski J
AD  - Cardiology Unit, John Paul II Western Hospital, ul. Daleka 11, 05-825 Grodzisk 
      Mazowiecki, Poland.
FAU - Kowalik, Robert
AU  - Kowalik R
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Cacko, Andrzej
AU  - Cacko A
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Niewinski, Grzegorz
AU  - Niewinski G
AD  - Department of Anesthesiology and Intensive Care, Medical University of Warsaw, 
      Banacha 1A, 02-677 Warsaw, Poland.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Opolski, Grzegorz
AU  - Opolski G
AD  - I Katedra i Klinika Kardiologii, Poland.
FAU - Grabowski, Marcin
AU  - Grabowski M
AD  - I Katedra i Klinika Kardiologii, Poland.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200107
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Sodium Potassium Chloride Symporter Inhibitors)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - W31X2H97FB (Torsemide)
SB  - IM
MH  - Aged
MH  - Comparative Effectiveness Research
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Furosemide/adverse effects/*therapeutic use
MH  - Heart Failure/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Poland
MH  - Preliminary Data
MH  - Recovery of Function
MH  - Sodium Potassium Chloride Symporter Inhibitors/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Torsemide/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC8083045
OTO - NOTNLM
OT  - heart failure
OT  - hospitalization
OT  - loop diuretics
OT  - prognosis
OT  - symptoms
COIS- Conflict of interest: None declared
EDAT- 2020/01/08 06:00
MHDA- 2020/08/04 06:00
PMCR- 2020/01/22
CRDT- 2020/01/08 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2019/11/23 00:00 [accepted]
PHST- 2019/11/17 00:00 [revised]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/01/22 00:00 [pmc-release]
AID - VM/OJS/J/65083 [pii]
AID - cardj-26-6-661 [pii]
AID - 10.5603/CJ.a2019.0114 [doi]
PST - ppublish
SO  - Cardiol J. 2019;26(6):661-668. doi: 10.5603/CJ.a2019.0114. Epub 2020 Jan 7.